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Summary 
The BALB/c Meth A sarcoma carries a p53 missense mutation at codon 234, which occurs in 
a peptide, termed 234CM,  capable of being presented to cytotoxic T  lymphocytes (CTL) by 
H-2K  d molecules (Noguchi, Y., E.C. P,  ichards, Y.-T. Chen, and L.J.  Old.  1994.  Proc. Natl. 
Acad.  Sci.  USA.  91:3171-3175).  Immunization of BALB/c mice with bone marrow-derived 
dendritic cells (DC), generated in the presence of granulocyte macrophage colony-stimulating 
factor and interleukin 4, and prepulsed with the Meth A p53 mutant peptide, induced CTL 
that specifically recognized peptide-pulsed P815 cells, as well as Meth A cells naturally express- 
ing this epitope. Immunization with this vaccine also protected naive mice from a subsequent 
tumor challenge, and it inhibited tumor growth in mice bearing day 7 subcutaneous Meth A 
tumors. We additionally determined that immunization of BALB/c mice with DC pulsed with 
the p53 peptide containing the wild-type residue at position 234, 234CW, induced peptide- 
specific CTL that reacted against  several methylcholanthrene-induced BALB/c sarcomas, in- 
cluding CMS4 sarcoma, and rejection of CMS4 sarcoma in vaccination and therapy (day 7) 
protocols. These results support the efficacy ofDC-based, p53-derived peptide vaccines for the 
immunotherapy of cancer. The translational potential of this strategy is enhanced by previous 
reports showing that DC can readily be generated from human peripheral blood lymphocytes. 
D 
uring the past few years, a number of CTL-defined, 
tumor-related peptides have been identified in human 
cancers, and attempts are being made for their clinical ap- 
plication (1-6). An essential aspect ofpeptide-based vaccine 
development is the identification of adjuvants that facihtate 
the induction of antitumor immune responses, particularly 
antitumor CTU These cells have been shown to be crucial 
effectors in antitumor immune responses in preclinical as well 
as  clinical  settings  (7).  Optimal  induction  of CTL is be- 
lieved to require an initial encounter with antigenic pep- 
tides presented by so-called "professional" APC. Dendritic 
cells (DC) 1 are presently considered the most potent APC, 
based in part on the demonstrated ability ofpeptide-pulsed 
DC  to prime naive CTL in vitro and in vivo (8-10).  As 
such, DC offer a potentially promising vehicle for the de- 
livery of immunotherapeutic peptides in the treatment of 
cancer and infectious diseases (11). 
~Abbreviations used in this paper: BM, bone marrow; CM, complete me- 
dium; CS, circumsporozoite;  DC, dendritic  cells; LLO, hsteriolysin  O. 
Preclinical models  are  needed,  however,  to  guide  the 
clinical development of DC-based immunotherapy for can- 
cer  patients.  Immunization  with  bone  marrow  (BM)- 
derived DC (12,  13) pulsed with peptides capable of being 
recognized by CTL induces a strong specific CTL response 
in  several  mouse  models  tested  (14-17).  Using  CTL- 
defined peptides derived from OVA and human papilloma 
virus 16 (HPV16) E7 protein, as well as unfractionated class 
I MHC-binding peptides acid eluted from the chemically 
induced  C57BL/6  MCA205  sarcoma,  we  have  already 
demonstrated that  administration  of peptide-pulsed,  DC- 
based vaccines can immunize mice in vaccine and therapy 
settings (14-16). The recent description of simple methods 
to generate large numbers  of DC  from human PBL cul- 
tured  in  the  presence  of GM-CSF  pls  IL-4  and  their in 
vitro use to obtain CTL (18,  19) suggests  the feasibility of 
DC-based vaccine strategies for cancer immunotherapy in 
humans. 
The  majority  of antitumor  cellular responses  presently 
characterized in humans involve CTL directed against  self 
peptides derived from ectopically expressed or lineage-spe- 
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al.  recently described two distinct melanoma epitopes aris- 
ing from point mutations,  though the appearance  of these 
epitopes  thus  far are confined to tumors of individual pa- 
tients (21, 22). Missense mutations in the p53 gene occur in 
approximately half of human cancers (23), and p53-derived 
peptides  may represent  ideal  targets  for cellular  immuno- 
therapy applicable to a wide range of  patients (24, 25). While 
peptides  encompassing point mutations  offer the potential 
of serving as tumor-specific epitopes,  this potential rests on 
the occurrence of a mutation within a peptide that can be 
processed  and  presented  to  CTL  by  a  given  class  I  aUo- 
morph.  Alternatively, it might be reasoned that since mu- 
tant p53  gene products  are often overexpressed in tumors 
(23, 26, 27),  enhanced presentation  of p53-derive peptides 
from nonmutated portions  of the molecule might accom- 
pany protein  overexpression.  Consequently,  an  optimistic 
scenario  arises  in  which,  by  analogy  with  responses  ob- 
served to lineage-specific epitopes,  tumor-selective cellular 
responses might be elicited  to wild-type p53  peptides,  in- 
dependent  of the p53 mutation in an individual  of a given 
MHC haplotype. 
We sought to determine whether DC-based vaccines that 
use both mutant and wild-type, p53-derived peptides could 
effectively elicit antitumor CTL in mice challenged with es- 
tablished  methylcholanthrene-induced  sarcomas.  Noguchi' 
et al.  (28, 29) recently described the use ofMeth A sarcoma 
p53-mutant and wild-type peptide  (p53(232_240)), designated 
234CM and 234CW, respectively, in vaccination protocols 
using BALB/c mice.  Mutant  peptide  234CM-based  vac- 
cines that use incomplete Freund's adjuvant (IFA) or QS-21 
adjuvant and IL-12 were shown to induce antipeptide CTL, 
while  only the QS-21/IL-12 vaccine induced Meth A  re- 
jection in vaccination and therapy settings.  Here,  we assess 
the efficacy of  immunization with syngeneic BM/DC pulsed 
with the 234CM peptide to induce CTL capable of recog- 
nizing Meth A  sarcoma presenting the naturally processed 
epitope,  as  well  as  peptide-pulsed  target  cells,  and  tumor 
rejection in vaccination and therapy settings.  The results of 
these  studies  confirmed the  potential  of peptide/DC  vac- 
cines to induce effective antitumor immune responses, and 
permitted us to extend our studies to an analysis of the effi- 
cacy  of the  p53  wild-type  peptide  234CW/DC  vaccine 
against several chemically induced BALB/c sarcomas known 
to be overexpressing p53. 
Materials and Methods 
Mice.  BALB/cJ and BALB/c  ￿  C57BL/6  (CB6F1)  female 
mice were obtained from The Jackson Laboratory (Bar Harbor, 
ME) and maintained in a specific pathogen-free facility. 
Tumors and Cell Lines.  The chemically induced BALB/c Meth A 
ascites sarcoma,  CMS series of chemically induced BALB/c sar- 
comas, and cell lines derived from them have been described  pre- 
viously (30). The DBA/2 mastocytoma P815 was obtained from 
the American Type Culture Collection (ATCC, Rockville, MD). 
All the chemically induced sarcomas  of BALB/c origin used  in 
this study express mutated p53 (26, 27, 31). The Meth A sarcoma 
has three p53 mutations, at codons 132, 168, and 234 (31), while 
CMS1 contains  a mutation in codon 239 (Cys to Phe)  (27). 
Antibodies.  Supernatants  containing  mAb  produced  by  the 
following hybridomas, which were obtained from ATCC, were 
used in this study: anti-H-2K  a (HB159),  -H-2D  a (HB104),  -CD4 
(TIB207),  -CD8 (TIB221), and -B220 (TIB146). 
Generation ofBM-derived  DC.  BM cells, which had been im- 
munodepleted oflymphocytes by treatment  with anti-B220,  -CD4, 
and  -CD8  mAb  and  rabbit  serum  as  C  source,  were  cultured 
overnight in 24-well plates  (Coming Inc., Coming, NY) to re- 
move adherent cells at a cell density of 106 cells/well  per ml com- 
plete medium (CM: RPMI  1640 supplemented with  10% FCS, 
antibiotics,  glutamine, and 50 p-M 2-ME). All reagents were ob- 
tained from GIBCO BRL, Gaithersburg,  MD). The nonadherent 
cells were harvested  and cultured at a cell density  of 2.5  X  10  s 
cells/well  per ml CM supplemented with  GM-CSF  (103 U/nil; 
Sigma  Immunochemicals, St.  Louis,  MO) alone or in combina- 
tion with either TNF-ix (100 U/ml; Genzyme, Boston, MA) or 
IL-4 (103 U/ml;  Schering-Plough, Kenilworth,  NJ)  in 24-well 
plates. Cells were harvested 8 d later (12, 13). 
Peptides.  Synthetic  p53-derived  peptides  containing  wild- 
type and mutant residues,  as determined by Arai  et al.  (31) and 
designated  as in Noguchi et al.  (28), were used in this study. The 
wild-type peptide p53(232_240)  , 234CW, has the sequence KYM- 
CNSSCM, while  that of the mutant peptide,  234CM,  is KYI- 
CNSSCM. The CMS1 p53 peptide containing the missense mu- 
tation  at  codon  239  as  determined  by  Halevy  et  al.  (27),  is 
KYMCNSSFM. In accordance with the nomenclature of Nogu- 
chi  et  al.  (28), this  peptide  is  designated  239CM.  Other  p53- 
derived peptides  used were p53030_t3s~ (LFCQLAKTC, 132CW; 
LFFQLAKTC, 132CM) and p53066_~74~ (MTEVVRtkCP, 168CW; 
MTGVVR.R.CP, 168CM) (28). The H-2Ka-binding Plasmodium 
bergii circumsporozoite (CS)-derived peptide, DSYIPSAEKI, was 
also used in these studies (32). Additional peptides  used in binding 
assays, described  below, include  the listeriolysin O  (LLO)-derived 
peptide LLO(91_99) (GYKDGNEYI), an LLO analogue,  LLO(Y2F) 
(GFKDGNEYI), and the OVA-derived peptide OVA(257_264) (SI- 
INFEKL) (33). All peptides  were synthesized  by standard  F-moc 
chemistry and purified by HPLC. 
Radiolabeled Peptide Binding.  Peptide  LL0(9~_99  ) was modified 
by replacing Tyr at P2 with Phe to produce the pepfde LLO(Y2F), 
containing  a  single  Tyr  at  P8  available  for iodination  by  the 
chloramine T  method. LLO(91_99  ) has been shown previously to 
bind to H-2K  d with high affinity (33); in the present assay system, 
the substituted  analogue LLO(Y2F) was found to bind with an af- 
finity comparable to that of the parent peptide.  Competitive inhi- 
bition of 125I-LLO(Y2F) binding to H-2K  d molecules on live cells 
was performed according to a previously published method (34). 
Specific binding is defined as the cpm bound in the absence  of 
cold peptide minus the cpm bound in the presence  of 100 p,g/nil 
cold LLO(Y2F). 
Reverse Transcription and PCR (RT-PCR).  Total cellular RNA 
was  prepared  using the RNeasy kit  (Qiagen  Inc.,  Chatsworth, 
CA).  cDNA synthesis was performed using the Superscript  Pre- 
amplification System from GIBCO BRL (Gaithersburgh,  MD) as 
previously described  (35). For each reaction, 2 p-g of RNA were 
reverse  transcribed  using random hexamer according to the proto- 
col supplied by GIBCO BRL. The cDNA was amplified using 100 
pmol  each  of p53.1  (5'-ATG.TGC.ACG.TAC.TCT.CCT-3') 
and  antisense  p53.2  (5'-GTG.GAT.GGT.GGT.ATA.CTC-3') 
for amplification  from bp 360 to 692, which represents  amplifica- 
tion from the expressed product of the 3' end ofexon 4 to the 5' 
end ofexon 7 (the sequence of primer p53.1  is from exons 4 and 
1358  p53-based  Immunotherapy of  Murine Sarcomas 5) and p53.3 (5'-GAG.TAT.ACC.ACC.ATC.CAC.-3')  and anti- 
sense  p53.4  (5'-TTC.TTC.TTC.TGT.ACG.GCG-3')  for  am- 
phfication from bp 675  to  855,  which represents  amplification 
from the expressed product of the 5' end of exon 7 to the middle 
ofexon 8 (31, 36). Samples were also reverse transcribed and am- 
plified  using primers  specific  for  actin  (Clontech Laboratories, 
Palo Alto, CA) to verify that the RNA was intact and could be 
reverse transcribed and amplified.  Samples were amplified for 30 
cycles in a DNA Thermal Cycler (Perkin-Elmer, Norwalk, CT) 
using the following conditions: 94  ~ for 1 min, 49  ~ for 2 min, 72  ~ 
for 3 min, followed by 15 min at 72  ~ PCR products were identi- 
fied on ethidium bromide-stained 1% agarose gels. 
Cloning and DNA Sequencing.  cDNA  products  were  ligated 
directly into the pCRII vector using the TA cloning kit (Invitro- 
gen, San Diego,  CA)  or hgated after isolation of specific bands 
from 1% low melting point agarose  (FMC BioProducts, Rock- 
land, ME) gels. Plasmid DNA was prepared after liquid culture of 
isolated recombinant colonies using standard mini-prep methods. 
Double-stranded DNA was  sequenced on both strands  by the 
dideoxy chain termination methods using Sequenase  TM  Version 
2.0 (U.S. Biochemical Corp., Cleveland, OH) with the M13 re- 
verse-sequencing  primer and T7 sequencing primer. 
Immunization  of Mice with DC-based  Peptide Vaccines.  BM- 
derived  DC,  grown in the  presence  of GM-CSF alone or in 
combination with either TNF-ot or IL-4, were incubated with 
peptides  at a concentration of 10 Ixg/ml per 106 DC/ml CM for 
2  h  at  37~  The  cells  were  harvested  by  centrifugation and 
washed with PBS, and irradiated  (3,000 rad) before use. Groups 
of three to five mice received two weekly intravenous injections 
of 10  s DC or peptide-pulsed DC (14). 7 d after the last immuni- 
zation, mice were killed and their spleens removed for in vitro re- 
stimulation or challenged bilaterally subcutaneously  with in vivo- 
grown Meth A sarcoma, 3.5  ￿  105 cells, or CMS4, 1.5 or 2.5  ￿ 
10  s cells. In the Meth A tumor model, the efficacy of DC-based 
peptide vaccines  was directly compared to that of IFA admixed 
with the 234CM peptide. Tumor growth was monitored every 7 d. 
Fisher's exact  method  or  the  Student's t  test  were  performed 
to interpret the  differences  between experimental groups  (pre- 
sented as mean +  SEM).  Two-sided P values  (t test) or signifi- 
cance at 95% confidence limits are presented for individual exper- 
iments. 
In Vitro Restimulation with Peptides.  Groups of mice that  had 
been immunized with various peptide-based vaccines were killed 
1 wk after the last immunization, and their spleens were removed 
for in vitro restimulation by peptide-pulsed splenocytes prepared 
by the addition of 10 ~g peptide to 107 splenocytes  in 1 ml CM 
followed by a 3-h incubation at  37~  The nonadherent lym- 
phocytes obtained from each  experimental group were restimu- 
lated at a cell density of 106 lymphocytes/4 ￿  106 peptide-pulsed 
splenocytes per 2 ml CM in 24-well plates. The cultures were in- 
cubated in a  5%  C02-humidified atmosphere for 7  d  and har- 
vested. 
Cell-mediated Cytotoxidty Assays.  In vitro-restimulated  lympho- 
cytes were tested for their cytolytic reactivity against BALB/c sar- 
comas, P815 and peptide-pulsed P815 target cells in standard 4-h 
SlCr release assays using 96-well round-bottomed plates.  Target 
cells were radiolabeled with 100 p~Ci Na2-SlCrO4/2  ￿  106 cells 
for 1 h at 37~  peptide-pulsed P815 cells were prepared by incu- 
bating P815 cells with the radiolabel  and peptide at a concentra- 
tion of 10 ~,g/ml. In mAb-blocking  experiments, hybridoma su- 
pernatants were added at a final dilution of 1:10. Maximum and 
spontaneous release, as well as the percentage of specific 51Cr cpm 
release, were determined by standard procedures. 
Treatment of  Tumor-bearing Mice with  Peptide-pulsed Vaccines. 
Groups of five  mice each  bearing established  7-d-old sarcomas 
were injected intravenously with 10  s DC(GM-CSF/IL-4) either 
unpulsed or pulsed with 10 b~g/ml peptide 7- and 14-d after chal- 
lenge. Tumor growth was monitored as detailed above. 
Results 
Binding of  p53-drived Peptides to Class I MHC.  Peptide- 
binding inhibition experiments  confirmed  that  234CM, 
234CW, and 239CM p53 peptides are capable of binding 
to  H-2K  a  (Fig.  1).  Inhibition was  observed for both  the 
234CW and 234CM peptides,  in addition to  the positive 
controls LLO/LLO(Y2F). No inhibition was observed for 
the p53-derived peptides  132CW/CM  and 168CW/CM, 
consistent with their lack of immunogenicity,  as previously 
reported  (28).  The data indicated that 234CM is a poorer 
binder than 234CW or 239CM peptides, producing only 
30% inhibition of 12SI-LLO(Y2F) binding at the relatively 
high concentration of 100 nM. Based on reported studies 
examining  binding of various peptides to a number of class I 
allomorphs (37-39), peptides exhibiting high affinity bind- 
ing normally produce half-maximal inhibition at a concen- 
tration  (ICs0  value)  well below  100  nM,  while  peptides 
binding with  moderate  to  low  affinity have  IC50 values 
near or above 100 nM. 
Tumor Rejection--inducing Activity of Peptide-pulsed DC-based 
Vaccines.  BM-derived DC  generated in the  presence  of 
GM-CSF alone or  in combination with  TNF-et or  IL-4 
were  pulsed with  the  234CM  and  234CW  peptides  and 
evaluated for their efficacy in protecting mice from a lethal 
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t25  Competitive inhibition of  I-LLO0(2F)  binding to H-2K  a 
molecules on P815 cells. Peptides at a concentration of 100 nM were 
tested for their capacity to inhibit binding of a trace concentration (<0.5 
nM) of radiolabeled peptide. The LLO/LLO(Y2F) and the H-2Kt-pre - 
sented peptide OVA were used as the postive and negative controls for 
this assay. Total and nonspecific  cpm bound for the experiment shown 
were 9,947 and 88 cpm, respectively. 
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Figure 2.  Meth A p53 234CM peptide-DC vaccine protects BALB/c 
mice from a subsequent challenge with Meth A sarcoma. Groups of five 
mice each were immunized twice by intravenous injection with vaccines 
consisting of the 10 Ixg/ml 234CM peptide admixed with IFA or pulsed 
onto  105 BM-derived DC generated in the presence of GM-CSF, GM- 
CSF/TNF-(x, or GM-CSF/IL-4, before challenge with 3.5 ￿  105 Meth 
A sarcoma. Tumors were measured on the indicated days. Data are repre- 
sentative of three experiments performed. 
challenge of the Meth A  sarcoma (Fig. 2). All three popula- 
tions  of BM-derived DC  used in  this  experiment  express 
elevated levels of class  II MHC  and  costimulatory mole- 
cules, B7.1  and B7.2  (13). The DC(GM-CSF/IL-4), how- 
ever,  express higher levels of these antigens than the other 
two DC populations. In addition, DC(GM-CSF/IL-4) are 
more potent stimulators of the allogeneic MLR than either 
DC  generated  in  the  presence  of GM-CSF  alone  or  in 
combination with TNF-o~  (14,  15).  Similarly, human  DC 
generated in the presence of GM-CSF and IL-4 have been 
shown  to  be  more  effective stimulators  of an  MLR  than 
DC(GM-CSF)  or  (GM-CSF/TNF-ct)  (19).  The  dose  of 
peptide-pulsed DC  used in this experiment was  105  cells/ 
immunization. It was chosen primarily on basis of the pre- 
viously reported  ability of this  number  of peptide-pulsed 
DC  to induce antipeptide CTL  (10,  17). A  higher dose of 
peptide-pulsed DC  (106)  had been  shown  to induce non- 
specific cytotoxic effector cells (17).  Controls for these ex- 
periments included untreated mice, as well as those immu- 
nized with  IFA alone or admixed with either the 234CM 
or 234CW peptide. 
Of the 12 types of vaccines tested, the only one found to 
be effective in protecting mice against Meth A  tumor chal- 
lenge  consisted  of DC(GM-CSF/IL-4)  pulsed  with  the 
234CM peptide (Fig. 2). Although 234CM/DC(GM-CSF/ 
TNF-c~)  enhanced  the  resistance  of the  mice  to  tumor 
challenge,  its  effect  was  not  statistically significant.  Mice 
immunized with vaccines consisting of 234CM pulsed onto 
GM-CSF-generated DC  or admixed with  IFA were inef- 
fective,  as  were  all  of the  wild-type 234CW-pulsed  DC 
vaccines. 
Induction of Anti-Meth A  CTL by Peptide-pulsed DC  Vac- 
cines.  Based on the proven ettlcacy of the 234CM-pulsed 
DC  (GM-CSF/IL-4)  vaccine  in  protecting  mice  against 
Meth A sarcoma, we analyzed similarly immunized mice for 
induction of anti-Meth A  CTL.  Controls for this analysis 
included lymphocytes obtained from naive mice and mice 
treated with DC alone or 234CM admixed with IFA. Sple- 
nocytes obtained from these groups of mice were restimu- 
lated in vitro with 234CM-pulsed splenocytes, and the result- 
ing effector cells were evaluated for their cytolytic reactivity 
against P815, 234CM-pulsed P815, and Meth A target cells. 
Antipeptide CTL were obtained from mice immunized with 
either 234CM-DC  or 234CM-IFA vaccines (Fig. 3).  Only 
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Figure  3.  Cytotoxic  reactivi- 
ties of effector cells induced  in 
mice  by  immunization  with 
Meth  A  p53  mutant  peptide- 
based  vaccines. The  vaccines 
used  consisted of the  234CM 
peptide  admixed  with  IFA  or 
pulsed  onto  DC(GM-CSF/ 
Ig-4).  Splenocytes (A-C)  ob- 
tained from the various groups of 
immumzed  mice were  restimu- 
lated  in  vitro  with  234CM- 
pulsed  splenocytes.  The  cyto- 
toxic  reactivity  of  effectors 
against P815 (A), 234CM-pulsed 
P815 (B), and Meth  A (C) tar- 
gets was determined in standard 
4-h SlCr release assays  at the E/T 
ratios indicated. Data are repre- 
sentative  of  three  experiments 
performed. The SEM was in all 
cases <15% of the mean values. 
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Figure 4.  Blocking of the cytotoxic activity  of anti-Meth A  CTL by 
mAb. The anti-Meth A CTL were tested at an E/T ratio of 50:1,  and in 
the presence of hybridoma supernatants at a final dilution of 1:10. 
the 234CM-DC vaccine, however, induced effectors with 
cytolytic reactivity against Meth A target cells (Fig.  3). The 
anti-Meth  A  reactivity of these  effectors was blocked by 
anti-H-2K  d and -CD8 mAb, but not anti-H-2D  a or -CD4 
mAb (Fig.  4). 
Meth A  expresses two p53  transcripts:  one encodes the 
mutations at codons 168 and 234, while the other encodes 
the mutation at codon 132 (30).  Consequently, the Meth A 
sarcoma has the potential to express epitopes containing ei- 
ther the wild-type or mutant 234  codon.  The inability of 
the 234CW-based vaccines to induce an anti-Meth A im- 
mune response suggests, however, that either the 234CW/ 
DC vaccine did not induce antipeptide CTL or the level of 
this epitope presented by Meth A  sarcoma is not sufficient 
for effective recognition by anti-234CW CTL. 
Immunotherapeutic  Effects of  Administration  of  234CMo 
pulsed DC vaccines on Meth A-bearing Mice.  The effect of the 
234CM-pulsed  DC vaccine on the  growth  of established 
Meth A  tumors was evaluated after it was administered to 
mice 7 and 14 d after Meth A  challenge. As shown in Fig. 
5, treatment of five Meth A-bearing mice with this vaccine 
induced tumor rejection in three of the mice and inhibition 
of tumor growth in the remaining two mice. Administra- 
tion of DC alone or DC pulsed with the 234CW peptide 
had no beneficial effect on Meth A-bearing mice. 
Induction of Antitumor  CTL  by  234CW-pulsed  DC  Vac- 
cine.  We questioned whether anti-234CW CTL could be 
induced,  and if so, whether they would recognize tumors 
overexpressing p53. We determined that immunization of 
mice with a 234CW/DC  vaccine did induce effectors ca- 
pable of recognizing 234CW-pulsed P815  target cells.  In- 
terestingly, they also recognized untreated P815 cells. They 
did not recognize Meth A sarcoma or 234CM-pulsed P815 
cells.  Furthermore,  recognition  of 234CW-pulsed  P815 
targets was  inhibited  by the  H-2Ka-binding CS  peptide, 
but not by the nonbinding p53 168CM peptide (Fig.  6 A). 
These results  support  the  specificity of these  effectors for 
the wild-type or "self" p53 epitope, and they indicate that 
P815  cells naturally process this epitope. The anti-234CW 
effectors  were  also  tested  against  a  panel  of non-cross- 
reacting, chemically induced BALB/c sarcomas that over- 
express p53  (26,  27,  30).  The  panel  consisted  of CMS1, 
CMS3, CMS4, and CMS5, and the effectors recognized all 
of the sarcomas except CMS1  (Fig.  6  B).  Recognition  of 
the  three sarcomas was blocked by anti-H-2K  a mAb, but 
not  anti-H-2D  a mAb,  indicating  that  the  effectors were 
class I MHC restricted. The tumor not recognized by these 
CTL, CMS1,  expresses a mutation at codon 239  (27).  In a 
separate experiment, we determined that the 239CM pep- 
tide induced  CTL reactive against CMS1  but not Meth A 
(data not shown). 
One  presumes that  the  four tumors  recognized by the 
anti-234CW CTL express elevated levels of p53 molecules 
with  missense  mutations  occurring  at  codons  other  than 
232-240. This would permit the cells to present the 234CW 
epitope at a level sufficient for it to be recognized by the 
CTL.  This hypothesis was confirmed for CMS4  sarcoma. 
The RT-PCR  product of CMS4  p53  exons 5  and 6  was 
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Figure  5.  The  effect  of adminis- 
tration  of 234CM/DC  vaccine  on 
mice bearing 7-d established  Meth A 
sarcoma.  Groups  of  five  BALB/c 
mice  were  challenged  with  3.5  X 
10  s Meth A. The mice were treated 
7  and  14 d  later by intravenous in- 
jection  of  10  s  irradiated  DC(GM- 
CSF/IL-4) alone or pulsed with  10 
Ixg/ml 234CW  or 234CM  peptide. 
Untreated  tumor-bearing  mice 
were  controls  for  this  experiment. 
Data  are  representative  of two  ex- 
periments performed. found to contain a missense  mutation at codon 194 (G to 
C; Val to Ala), while the RT-PCIL products of exons 7 to 
mid-8 were wild type. 
Since  thymocytes, as  well  as  mitogen-stimulated  lym- 
phocytes, have been  shown to  express  increased levels  of 
p53 (40),  we asked whether (a)  Con A-stimulated spleno- 
cytes would be recognized by 234CW-induced CTL; and 
(b) immunization of mice with 234CW/DC vaccines would 
have an immunosuppressive effect on the mice. We deter- 
mined that Con A-stimulated splenocytes were not recog- 
nized by anti-234CW CTL (8.3  +  1.1% vs  19.1  +-  2.8% 
for CMS4 and 3.6 -+ 0.5% for Meth A cells at an E/T ratio 
of  50:1)  and  that  234CW/DC-immunized mice  main- 
tained for 4  mo  remained visibly healthy throughout this 
time period. Moreover, immunization of 234CW-immune 
mice  with  the  unrelated H-2Kd-binding CS  peptide  in- 
duced CTL reactive against CS-pulsed P815 cells at a level 
comparable to that induced in control mice (49.2  +  6.7% 
for 234CW-immune mice vs 52.7  +  7.4% for CS-immu- 
nized control mice at an E/T ratio of 50:1). 
Tumor Rejection-inducing Activity of 234CW-pulsed DC-based 
Vaccines.  Based  on  the  observed  cytotoxic  reactivity  of 
anti-234CW CTL for CMS4 sarcoma, DC(GM-CSF/IL-4) 
pulsed with the  234CW peptide were  evaluated for their 
efficacy in protecting mice from a lethal challenge with the 
CMS4  sarcoma.  Controls for  these  experiments included 
untreated mice, as well as mice immunized with DC alone 
or 234CM-pulsed DC.  The only vaccine found to be ef- 
fective in protecting mice against the  CMS4  tumor chal- 
lenge  consisted  of DC  pulsed  with  the  234CW  peptide 
(Fig. 7). 
Immunotherapeutic Effects of Administration  of  234CW- 
pulsed DC  Vaccine to CMS4-bearing  Mice.  The  effect  of 
the  234CW-pulsed DC  vaccine on the  growth  of estab- 
lished CMS4 tumors was evaluated after its administration 
to mice 7 and 14 d after CMS4 challenge. As shown in Fig. 
8, treatment of five CMS4-bearing mice induced tumor re- 
jection in three of the mice and inhibition  of tumor growth 
in the remaining mice. Administration of DC alone or DC 
pulsed with either the 234CM or CS peptide had no bene- 
ficial effect on CMS4-bearing mice. 
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Figure 6.  Analysis  of cytolytic activity  of effectors induced in BALB/c 
mice by p53 234CW/DC vaccine. (A) Peptide inhibition of cytotoxic re- 
activity against  P815 and peptide-pulsed  P815 targets. (B) Cytotoxic reac- 
tivity against chemically  induced BALB/c sarcomas and blocking ofcyto- 
toxic reactivity by mAb. All assays were done at an E/T ratio of 50:1. 
Data are representative  of three experiments  performed. The SEM was in 
all cases < 15% of the mean values. 
Discussion 
We have demonstrated that administration of vaccines con- 
sisting of H-2Kd-binding wild-type or mutant p53(232_240) 
peptides pulsed onto BM-derived DC  were  highly effec- 
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Figure  7.  p53 wild-type 234CW 
peptide-DC  vaccine  protects 
BALB/c  mice from a  subsequent 
challenge  with  CMS4  sarcoma. 
Groups of five mice each were im- 
munized twice by  intravenous in- 
jection  with vaccines consisting of 
105  DC(GM-CSF/IL-4)  alone or 
pulsed  with  10  p~g/ml  mutant 
234CM or wild-type 234CW pep- 
tide before challenge  with 2.5 ￿  105 
CMS4 sarcoma. Data are representa- 
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Figure  8.  The effect of adminis- 
tration of  wild type p53 peptide vac- 
cine on mice bearing 7-d established 
CMS4  sarcoma.  Groups of  five 
BALB/c mice were challenged with 
1.5  ￿  10  s CMS4. The mice were 
treated 7 and 14 d later by intrave- 
nous  injection  of  I0  s  irradiated 
DC(GM-CSF/IL-4)  alone  or 
pulsed with  10  ~g/ml  234CW  or 
234CM peptide. Untreated tumor- 
bearing mice were controls for this 
experiment. Data are representative 
of two experiments performed. The 
mean  tumor  diameter  of  mice 
treated with  the  234CW/DC vac- 
cine was  significantly smaller than 
that of  the control groups (P <0.05). 
mice.  Furthermore,  treatment of tumor-bearing mice with 
these vaccines was shown to have beneficial therapeutic ef- 
fects. Previously, Noguchi et al.  reported the successful in- 
duction  of p53  mutation-specific  CTL  using  the  mutant 
Meth  A  p53  peptide.  The  vaccines  used  consisted  of the 
234CM peptide  admixed with IFA or QS-21  (28,  29).  As 
observed in similar attempts  to induce  in vitro  or in vivo 
antitumor CTL, the resulting CTL were capable of recog- 
nizing peptide-pulsed target cells, but apparently not target 
cells expressing the naturally processed epitope (41). 
Dendritic  cells  are  known  to  be  highly  effective  APC 
(8).  In the present study, we directly compared the efficacy 
of peptide-based  vaccines consisting of three types of BM- 
derived DC populations (those generated in the presence of 
GM-CSF  alone or in combination with TNF-ot or IL-4), 
with  IFA admixed with  the  Meth  A  p53  mutant  234CM 
peptide.  As with other models we have analyzed, vaccines 
using DC(GM-CSF/IL-4)  were  the  most effective in  in- 
ducing antitumor immune responses (14). This finding un- 
derscores the importance of effective adjuvant/delivery sys- 
tems  for  the  generation  of CTL  of sufficient  affinity  to 
recognize the naturally processed epitope,  and DC appear 
to be the vehicle of choice in this regard. It is worth noting 
that the phenotype and function of the murine DC used in 
this study are comparable to those of human blood-derived 
DC grown in the presence of GM-CSF and IL-4 (19). 
Because of the high frequency of mutations occurring in 
the p53 gene in human tumors, the product of this mutated 
gene  is  an  attractive  candidate  for  tumor  peptide-based 
vaccines and immunotherapy. The applicability of anti-p53 
based  immunotherapy  of  cancer  might  be  greatly  en- 
hanced,  however,  if p53  wild-type  or  "self"  epitopes,  as 
well as mutant "nonself" epitopes, could be used as immu- 
nogens.  Our success in using a  class  I  MHC-binding  p53 
wild-type epitope to induce tumor resistance  suggests that 
p53 wild-type epitopes might be used in peptide-based im- 
munotherapy of human cancer.  The translational potential 
of such  therapy  is  enhanced  by the  fact  that  HLA-A2.1- 
binding  human  p53  wild-type  and  mutant  epitopes  have 
been identified (24, 25), although it is presently not known 
whether  they are  naturally processed  and  presented.  Fur- 
thermore,  while we have observed that induction of anti- 
p53  wild-type  CTL responses  had no  obvious deleterious 
effects in naive mice, the potential for inducing an inappro- 
priate  response  directed  to  nontransformed  cells  in  vivo 
warrants further study. 
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